AWRE vs SKYE Comparison

Aware Inc provides biometric identity and authentication solutions. Its Awareness Platform transforms biometric data into actionable intelligence, allowing its clients to verify identities and authenticate access and transactions. The company's products span multiple biometric modalities, including fingerprint, face, iris, and voice. It offers: a broad range of biometrics software products and solutions, including platforms like AwareSDK, AwareABIS, AFIX Suite of Products, Awareness Platform, and WebEnroll; software components such as SDKs, APIs, and applications that customers use to develop their systems into more effective solutions; and several program management and software engineering services. Aware earns maximum revenue from the U.S., followed by the UK and the rest of the world.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.